Celltrion’s Rituximab Biosimilar Enjoys A Market Share Of More Than A Third In Europe
Within 18 months of hitting European markets, Celltrion’s rituximab biosimilar of Roche’s MabThera/Rituxan oncology and autoimmune diseases brand has captured a share of more than a third; meanwhile the Korean firm has updates for its trastuzumab and infliximab biosimilar medicines.
You may also be interested in...
Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).
Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.